GUTS (Fractyl Health, Inc. Common Stock) Stock Financials & Earnings

GUTSFractyl Health, Inc. Common Stock

Mkt Cap$35M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$3,000

Net Income (TTM)-$122M

EPS (TTM)-$2.28

Free Cash Flow (TTM)-$87M

Gross Margin-9566.7%

Op. Margin-3291400.0%

Net Margin-4073233.3%

FCF Margin-2893766.7%

P/S Ratio (TTM)11659.3x

P/E Ratio (TTM)—

YoY Rev Growth-96.9%

Employees—

Earnings Reports

Next: Q4 2025 · Mar 16

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$0	$0	-$11M
Q1 23	$5K	$2K	-$12M
Q2 23	$72K	$25K	-$12M
Q3 23	$36K	-$73K	-$14M
Q4 23	$7K	$5K	-$13M
Q1 24	$33K	$14K	-$22M
Q2 24	$43K	$19K	-$23M
Q3 24	$14K	$7K	-$24M
Q4 24	$3K	$3K	-$25M
Q1 25	$0	$0	-$25M
Q2 25	$0	$0	-$26M
Q3 25	$0	-$290K	-$23M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 22	$9M	—	—
Q1 23	$9M	—	—
Q2 23	$9M	—	—
Q3 23	$9M	$6M	—
Q4 23	$10M	—	—
Q1 24	$14M	—	—
Q2 24	$17M	—	—
Q3 24	$19M	—	—
Q4 24	$20M	—	—
Q1 25	$19M	—	—
Q2 25	$21M	—	—
Q3 25	$17M	—	$5M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$49M	$0	$49M
Q1 23	$0	$0	$0
Q2 23	$28M	$0	$28M
Q3 23	$45M	$0	$45M
Q4 23	$34M	$0	$34M
Q1 24	$121M	$0	$121M
Q2 24	$102M	$0	$102M
Q3 24	$85M	$0	$85M
Q4 24	$67M	$0	$67M
Q1 25	$42M	$0	$42M
Q2 25	$22M	$0	$22M
Q3 25	$78M	$0	$78M

Shares Outstanding

Revenue Per Employee

Revenue / Employee